Mpox Resource Center

The National Coalition for LGBTQ Health’s Mpox Resource Center provides information, data, links to resources, and general news from multiple sources on mpox in the United States on topics including prevention, transmission, testing, and treatment.

The National Coalition for LGBTQ Health has launched a microgrant program* with LGBTQ organizations to support their efforts to increase mpox awareness through dissemination of information and educational resources.

The awareness and educational materials are designed to further empower communities with knowledge and resources for dissemination, enabling them to more fully engage in preventive measures and raise awareness of vaccination and its equitable access. Micrograntee outreach efforts are supported by the Coalition’s Mpox Resource Center, which provides information, data, links to resources, and general news from multiple sources on Mpox in the United States and globally.

* The microgrant program is made possible through a grant from Bavarian Nordic. Inc.

Webinars and Events

WHO EPI-WIN Webinar: Responding to Mpox — Community Protection

The WHO Director General declared mpox a Public Health Emergency of International Concern (PHEIC), as new clade of the virus, clade 1b, spread rapidly while clade 1a and clade 2 are also spreading rapidly in many African countries. Outside of Africa, mpox has recently been reported in Sweden, Thailand and Pakistan. As the virus spreads, affected groups are also shifting.Different regions are facing different challenges. Engaging and protecting the affected communities as our understanding of the disease and its spread evolves, is critical.

This webinar aims to highlight the work in protecting communities in the current mpox emergency and the evolving situation, including the specific needs of the different affected communities and how those can be addressed.

Resources from the CDC

It’s not clear how people were exposed to mpox, but early data suggest that gay, bisexual, and other men who have sex with men make up a high number of cases. However, anyone who has been in close contact with someone who has mpox is at risk. CDC is urging healthcare providers in the U.S. to be alert for patients who have rash illnesses consistent with mpox, regardless of whether they have travel or specific risk factors for mpox and regardless of gender or sexual orientation.

CDC is working with state and local health officials to identify people who may have been in contact with individuals who have tested positive for mpox, so they can monitor their health.

Stay current on CDC’s mpox resources online by visiting the What’s New & Updated page.

Latest Updates

BPHC Bulletin
The SNS has a limited supply of JYNNEOS doses that expire on October 31, 2024. To assist uninsured and underinsured individuals who would like to get vaccinated against mpox but have not yet due to cost and/or availability, ASPR will ship, at no cost, JYNNEOS vaccine doses to your health center starting on September 9, 2024. These vaccines are intended for people who are at high risk of mpox disease and who do not have health care coverage to pay for the vaccines.

Global strategic preparedness and response plan launched by WHO to contain mpox outbreak
The World Health Organization (WHO) today launched a global Strategic Preparedness and Response Plan to stop outbreaks of human-to-human transmission of mpox through coordinated global, regional, and national efforts. This follows the declaration of a public health emergency of international concern by the WHO Director-General on 14 August 2025.

NIH: Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen
Study highlights need for defined markers of mpox immunity to inform public health use.

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers.

Evidence-based interventions are needed to respond to current and future mpox outbreaks within and beyond the United States. To help meet domestic and international mpox response goals, CDC is urging clinicians to let patients with mpox know that oral tecovirimat is available through STOMP and encourage them to enroll. Providers should inform patients about STOMP so they can consider enrolling in the study. However, enrollment in the study is voluntary, and patients who decline to take part, or who do not meet the criteria to participate, can still obtain tecovirimat if recommended. For more information about obtaining TPOXX or about the STOMP study, visit www.cdc.gov/poxvirus/mpox/clinicians/obtaining-tecovirimat.html or https://www.stomptpoxx.org/main.

Information for Healthcare Providers: Tecovirimat (TPOXX) and Guidance for Tecovirimat Use pages are now live.

Mpox Vaccination Basics

Treatment Information for Healthcare Professionals

Media

National LGBTQ+ expert discusses how to keep safe during Atlanta Pride

Emory University’s WMRE on mpox and Atlanta Pride

Amid Global Emergency, FDA OKs Another Vaccine for Mpox
“All effective tools” are needed to combat mpox threat, expert says — Medpage Today

Global emergency declared over a new mpox outbreak. What to know in Florida — Miami Herald

WHO declares mpox outbreaks in Africa a global health emergency as a new form of the virus spreads — AP

Slight Mpox uptick reported for July — Windy City Times

UN health agency convening experts meeting to decide if mpox outbreak in Africa is global emergency — AP

WHO to decide this week if mpox Africa outbreak is a global emergency — Politico

If You Are Sick

Disinfecting Home and Other Non-Healthcare Settings

What to Do If You Are Sick

TRACKERS

Mpox Vaccine Donation Tracker
A weekly updated tracker from ThinkGlobalHealth for vaccine donations announced in response to the mpox Clade I outbreak

VIDEOS

FAQ videos from Kaiser Family Foundation, rights-free and designed for sharing

Resources from Greater Than AIDS

Mpox Resources from Greater Than HIV
Demetre Daskalakis, MD, MPH, Acting Director of the National Center for Immunization and Respiratory Diseases at the CDC, provides the latest on mpox in this FAQ series from KFF and CDC.